Objective To investigate the efficacy of adriamycin injection around trigeminal ganglion via foramen ovale for treatment of trigeminal neuralgia under the guidance of X-ray and neurostimulator.Methods 0.5% adriamycin 0.5 ml was injected into foramen ovale under the guidance of X-ray and neurostimulator in 78 patients with primary trigeminal neuralgia.Correct location of needle tip wax confirmed by lidocaine injection.THe patients were followed up for 24 months after adriamycin injection.The rate of effectiveness,excellent/good rate,compile remission rate and recurence rate were calculated.The complications were observed.Results On the day of treatment,and at 7 days and 1,6,12,24 months after treatment,the complete remission rate was 21%,18%,51%,45%,43%,and 39%respectively,the excellent/good rate 42%,41%,68%,65%,62%,and 54%respectively,and the rate of effectiveness 76%,82%,92%,91%,78%,and 70%respectivdy.The recurrence rate was 3%,20%and 35%at 6,12 and 24 months after treatment respectively.Facial numbness developed in 17 patients and disappeared after 8-12 months.No severe complication occurred.Conclusion Adriamycin injection around trigeminal ganglion via foramen ovale under the guidance of X-ray and neuronstimulator for treatment of trigeminal neuralgia is effective and safe.

Objective: To evaluate the feasibility and potential value of comprehensive geriatric assessment (CGA) in elderly (≥60 years) patients with newly diagnosed acute myeloid leukemia (AML) in China. Methods: The CGA results of 83 newly diagnosed AML (non-APL) patients from 16 hospitals in Beijing and Tianjin between March 2016 and December 2017 were prospectively collected and analyzed. The clinical data, treatment and follow-up information were also collected. Results: Of 83 newly diagnosed elderly AML patients, 81 patients (97.6%) completed all designated CGA assessment. The median number of impaired scales of the CGA assessment in the studied population was 2(0-6). Sixteen patients (19.3%) showed no impairments according to the geriatric assessment scales implem ented by this study. The distributions of impaired scales were as follows: impairment in ADL, 55.4%; IADL impairment, 42.2%; MNA-SF impairment, 48.2%; cognitive impairment, 15.7%; GDS impairment, 31.7%; HCT-CI impairment, 19.5%, respectively. In patients with "good" ECOG (n=46), the proportion of impairment for each CGA scale ranged from 6.5% to 37.0% and 32 patients (68.9%) had at least one impaired CGA scale. Survival analysis showed that the number of impaired scales of the CGA was significantly correlated with median overall survival (P=0.050). Conclusions CGA was a tool with feasibility for the comprehensive evaluation in elderly AML patients in China. Combined with age and ECOG, CGA may be more comprehensive in assessing patients’ physical condition.